Galleri® in the Medicare Population
Studies have shown that older individuals experience a greater burden of cancer due to higher mortality rates compared to younger individuals. The REACH study is a clinical study to learn how the Galleri® multi-cancer early detection (MCED) test can screen for cancer through a simple blood draw. Led by GRAIL, the purpose of this study is to understand the real-world clinical value, benefit and safety of the Galleri test in the Medicare eligible patient population.
The trial will evaluate if using the Galleri test alongside existing usual medical care can help find cancer early and to see if the Galleri test decreases the number of late stage cancer diagnoses. Evaluating the Galleri test in Medicare recipients will provide important data on the potential harms and benefits of MCED screening in older individuals.
REACH Study Eligibility
The REACH study is currently enrolling people who are over 50 years old and are enrolled in either traditional Medicare or Medicare Advantage, and who have not taken the Galleri test in the past. Participants in the REACH study will be eligible to receive up to 3 annual Galleri tests in this study. After the first Galleri test, you and your healthcare provider will decide if you should test again.
Who can take part in the REACH study?
- People aged 50 years or older with Medicare coverage, including traditional Medicare or Medicare Advantage
- Have not been diagnosed or treated for cancer in the last 3 years
- Not undergoing clinical evaluation for suspicion of cancer
- Registered with one of the health systems participating in the REACH study
To enroll, you must be a registered patient at participating sites.
Contact your local site to learn more.
California
Sutter Health
Auburn | Davis | Elk Grove | Fairfield | Modesto | Palo Alto | Roseville | Sacramento | Santa Cruz | Santa Rosa | Sunnyvale
Contact: Debbie A Jacobs
916‑746‑2161 | clinicalresearch@sutterhealth.org
Memorial Care
Long Beach
Contact: Ana Fuentes
562-760-6849 | afuentes1@memorialcare.org
Indiana
Community Health Network
Anderson | Fishers | Indianapolis | Kokomo
Contact: Joy Koglin
317-621-7724 | jkoglin@ecommunity.com
Louisiana
Oschner Health
Baton Rouge | Covington | Lafayette | Marrero | Metairie | New Orleans
Contact: Ellen Lovell
504‑842‑8196 | Ellen.Lovell@Ochsner.org
Missouri
Mercy Health
St. Louis | Springfield
Contact: Damon Broyles
MercyResearchREACHStudy@Mercy.net
Oregon
Oregon Health & Science University
Beaverton | Hillsboro | Portland
Contact: Diana Potts
503‑418‑8150 | REACH@ohsu.edu
What does participation involve?
As a participant in the REACH study, you will be asked to:
- Read and sign an informed consent form that explains the study in full.
- Complete up to 3 annual blood draws.
- Complete questionnaires around the time of receiving each Galleri test, and annually during the study follow-up period of approximately 3 years.
About the REACH study
The REACH/Galleri-Medicare study is sponsored by GRAIL and will enroll approximately 50,000 Medicare beneficiaries who have received usual care plus a Galleri test with a matched comparator arm of beneficiaries who receive usual care alone. The REACH study is being conducted under the U.S. Food and Drug Administration’s (FDA) approval of an investigational device exemption (IDE) application. More information about the REACH Study is available on clinicaltrials.gov.
The Galleri MCED test is a new proactive tool to screen for cancer. Galleri is a blood test that screens for multiple cancers, most of which have no recommended screening and often go undetected until symptoms appear.
In the REACH study, the Galleri test is an investigational test with associated risks and benefits that are described in the study materials. Risks of the test include, but are not limited to, false-positive results (a cancer signal detected when cancer is not present), false-negative results (no cancer signal detected when cancer is present), and incorrect prediction of the origin of a cancer signal. The Galleri test should not replace any guideline-recommended screenings or other standard of care diagnostic or treatment options.
Resource Links
- About Galleri